Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

Lange's handbook of chemistry

Lange, N. A., & Speight, J. G. (1992) · Choice Reviews Online · doi:10.5860/choice.30-1849 · Cited by 7,163

STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES

Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,438

Structure of 20S proteasome from yeast at 2.4Å resolution

Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,265

Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å Resolution

Löwe, J., Stock, D., Jap, B. K., Zwickl, P., Baumeister, W. P., & Huber, R. (1995) · Science · doi:10.1126/science.7725097 · Cited by 1,540

Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids.

Kettner, C. A., & Shenvi, A. B. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42521-x · Cited by 294

The selective inhibition of thrombin by peptides of boroarginine.

Kettner, C. A., Mersinger, L. J., & Knabb, R. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44751-x · Cited by 254

Inhibition of serine proteases by peptidyl fluoromethyl ketones

Imperiali, B., & Abeles, R. H. (1986) · Biochemistry · doi:10.1021/bi00361a005 · Cited by 248

R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin

Matteson, D. S., Sadhu, K. M., & Lienhard, G. E. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00407a051 · Cited by 153

Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole

Edwards, P. D., Meyer, E. F., Vijayalakshmi, J., Tuthill, P. A., Andisik, D., Gomes, B. C., & Strimpler, A. M. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00031a046 · Cited by 145

Kinetic Characterization of the Chymotryptic Activity of the 20S Proteasome

Stein, R. L., Melandri, F. D., & Dick, L. R. (1996) · Biochemistry · doi:10.1021/bi952262x · Cited by 138

Recent Development in Novel Anticancer Therapies

Weinmann, H., & Ottow, E. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00210-8 · Cited by 10

Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD)

Huang, B., Li, J., Xu, X., Zheng, D., Zhou, Z., & Liu, J. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.10.001 · Cited by 9

Pseudomembranous Colitis following Bortezomib Therapy in a Myeloma Patient

Moon, S.-J., Min, C., Lee, D., Lee, S., Lee, J., Min, W.-S., Kim, C.-C., Kim, M., Park, G., & Kim, Y. (2007) · Acta Haematologica · doi:10.1159/000098699 · Cited by 9

The Proteasome: A Novel Therapeutic Target in Haematopoietic Malignancy

Magill, L., Walker, B., & Irvine, A. E. (2003) · Hematology · doi:10.1080/10245330310001604755 · Cited by 9

Academic–Industrial Collaboration: Toward the Consilience of Two Solitudes

Hanessian, S. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00488 · Cited by 9

Evaluation of dose-dependent effects of the proteasome inhibitor bortezomib in human platelets

Koessler, J., Etzel, J., Weber, K., Boeck, M., & Kobsar, A. L. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.031 · Cited by 8

Reduced graphene oxide‐based bortezomib delivery system for photothermal chemotherapy with enhanced therapeutic efficacy

Hu, Y., He, L., Ma, W., & Chen, L. (2018) · Polymer International · doi:10.1002/pi.5689 · Cited by 8

Cullin7 in tumor development: a novel potential anti-cancer target

Li, Y., Zang, A., Fu, J., & Jia, Y. (2021) · Neoplasma · doi:10.4149/neo_2021_201207n1324 · Cited by 8

Use of Proteasome Inhibitors

Downey-Kopyscinski, S. L., Florea, B. I., Overkleeft, H. S., & Kisselev, A. F. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im0910s109 · Cited by 8

Proteasome inhibitors and modulators of heat shock protein function

Kuhn, D. J., Zeger, E. L., & Orlowski, R. Z. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.05.008 · Cited by 8

The Unfolded Protein Response as a Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Garshott, D. M., Bechler, S. A., Burchhardt, D. M., O’Brien, P. S., Yoo, G. H., Chiego, D. J., Rehman, A. O., Callaghan, M. U., & Fribley, A. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-27647-2_10 · Cited by 8

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells

Shalem-Cohavi, N., Beery, E., Nordenberg, J., Rozovski, U., Raanani, P., Lahav, M., & Uziel, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102509 · Cited by 8

Novel boron‐containing compound, halogenated boroxine, induces selective cytotoxicity through apoptosis triggering in UT‐7 leukemia

Hadžić, M., Pojskić, L., Lojo-Kadrić, N., Haverić, A., Ramić, J., Galić, B., & Haverić, S. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23005 · Cited by 8

Proteasome Inhibitor Anticancer Drug Bortezomib Redox Behaviour at a Glassy Carbon Electrode

Golea, D. A., Diculescu, V. C., Ţugulea, L., & Oliveira‐Brett, A. M. (2012) · Electroanalysis · doi:10.1002/elan.201200307 · Cited by 8

Platinum pyridinecarboxaldimine complexes containing boronate esters

Darwish, H. A., Scales, S. J., Horton, J. L., Nikolcheva, L. G., Zhang, H., Vogels, C. M., Saleh, M. T., Ireland, R. J., Decken, A., & Westcott, S. A. (2004) · Canadian Journal of Chemistry · doi:10.1139/v04-147 · Cited by 8

To Market, To Market—2003

Hegde, S. G., & Carter, J. (2004) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(04)39025-1 · Cited by 8

Bortezomib (Velcade): A First‐in‐Class Proteasome Inhibitor

Greener, B. S., & Millan, D. S. (2010) · Wiley eBooks · doi:10.1002/9780470768594.ch8 · Cited by 8

Proteasome Inhibition: Novel Therapy for Multiple Myeloma

Kaufman, J. L., & Lonial, S. (2006) · Oncology Research and Treatment · doi:10.1159/000091692 · Cited by 8

Modulation of Lonp1 Activity by Small Compounds

Zanini, G., Micheloni, G., Sinigaglia, G., Selleri, V., Mattioli, A. V., Nasi, M., Pierri, C. L., & Pinti, M. (2025) · Biomolecules · doi:10.3390/biom15040553 · Cited by 7

XPA tumor variant leads to defects in NER that sensitize cells to cisplatin

Blee, A. M., Gallagher, K., Kim, H.-S., Kim, M., Kharat, S. S., Troll, C. R., D’Souza, A., Park, J., Neufer, P. D., Schärer, O. D., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae013 · Cited by 7

Structural basis for allosteric modulation of M. tuberculosis proteasome core particle

Turner, M., Uday, A. B., Vėlyvis, A., Rennella, E., Zeytuni, N., & Vahidi, S. (2025) · Nature Communications · doi:10.1038/s41467-025-58430-0 · Cited by 7

Flow synthesis of an α-amino boronic ester as a key precursor of bortezomib drug

Desrues, T., Legros, J., Jubault, P., & Poisson, T. (2022) · Reaction Chemistry & Engineering · doi:10.1039/d2re00099g · Cited by 7

The potential of proteasome inhibition in the treatment of colon cancer

Konstantinopoulos, P. A., & Papavassiliou, A. G. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.9.1067 · Cited by 7

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome

Sridhar, S., Bhat, G., & Guruprasad, K. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-566 · Cited by 7

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma

Lee, K., Yun, T., Song, E. K., Na, I. I., Shin, H., Bang, S., Lee, J. H., Lee, S., Kim, J. H., Yoon, S., et al. (2005) · Journal of Korean Medical Science · doi:10.3346/jkms.2005.20.4.598 · Cited by 7

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint

Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n-v2 · Cited by 8

Natural Product and Synthetic Proteasome Inhibitors

Kim, K. B., & Crews, C. M. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-794-9_4 · Cited by 8

Bis-CF3-bipyridine Ligands for the Iridium-Catalyzed Borylation of N-Methylamides

Marcos‐Atanes, D., Jiménez‐Osés, G., & Mascarenas, J. L. (2025) · ACS Catalysis · doi:10.1021/acscatal.5c00933 · Cited by 6

The Proteasome as a Target for Cancer Treatment

Papandreou, C. N. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504060-00003 · Cited by 6

Methyl 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-4-nitrobenzoate

Jenkinson, S. F., Thompson, A. L., & Simone, M. I. (2012) · Acta Crystallographica Section E Structure Reports Online · doi:10.1107/s1600536812029650 · Cited by 6

Unstable Intermediates as Keys to Synthesis with Organoboron Compounds

Matteson, D. S. (2016) · ACS symposium series · doi:10.1021/bk-2016-1236.ch005 · Cited by 6

Biochemical and histomorphological findings in Swiss Wistar rats treated with potential boron-containing therapeutic - K2[B3O3F4OH]

Haverić, A., Durmić-Pašić, A., Alić, A., Mujezinović, İ., Smajlović, A., Ostojić, J., Ahatović, A., Hadžić, M., Prašović, S., Haverić, S., et al. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126642 · Cited by 6

Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line

Erkmen, T., Serdar, B. S., Ateş, H., Korkmaz, M., & Koçtürk, S. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-02802-2 · Cited by 6

A solid-phase approach for the synthesis of α-aminoboronic acid peptides

Daniels, B. E., & Stivala, C. E. (2018) · RSC Advances · doi:10.1039/c7ra13479g · Cited by 6

An original catalytic synthesis of boriran-1-ols

Khafizova, L. O., Khusainova, L. I., Tyumkina, T. V., Ryazanov, K. S., Popod’ko, N. R., & Dzhemilev, U. M. (2018) · Mendeleev Communications · doi:10.1016/j.mencom.2018.11.003 · Cited by 6

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

Madamsetty, V. S., Paulus, A., Akhtar, S., Manna, A., Rachamalla, H. K., Banerjee‬‬‬‬‬‬‬‬‬, R., Mukhopadhyay, D., & Chanan-Khan, A. A. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1775204 · Cited by 6

α-Aminoboronic acids, amine cyanoboranes, amine carboxyboranes and their derivatives

Takrouri, K., Dembistky, V. M., & Srebnik, M. (2005) · Studies in inorganic chemistry · doi:10.1016/s0169-3158(06)80009-5 · Cited by 6

Immunoblotting Methods for the Study of Protein Ubiquitination

Mimnaugh, E. G., & Neckers, L. Μ. (2003) · Humana Press eBooks · doi:10.1385/1-59259-181-7:179 · Cited by 6

Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer

Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6

Chemistry of α‐Aminoboronic Acids and their Derivatives

Dembitsky, V. M., & Srebnik, M. (2009) · Wiley eBooks · doi:10.1002/9783527631780.ch4 · Cited by 6

Half‐ and Mixed‐Sandwich Transition Metal Dicarbollides andnido‐Carboranes(–1) for Medicinal Applications

Schwarze, B., Gozzi, M., & Hey‐Hawkins, E. (2018) · Wiley eBooks · doi:10.1002/9781119275602.ch1.4 · Cited by 6

First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma Agents

Chan, A. M., Lowe, B. D., Cottingham, A. L., Eker, D. V., Aytenfisu, A. H., Jones, J. W., MacKerell, A. D., Pearson, R. M., & Fletcher, S. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00500 · Cited by 5

Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines

Dettmer, S., Theile, D., Schäfer, J. C., Seckinger, A., Burhenne, J., & Weiß, J. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1276-9 · Cited by 5

2-{2-[(4-Methoxyphenoxy)methyl]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane and N-(4-Ethoxybenzyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine: Molecular Structures Determined by Quantum-Chemical Calculations, NMR Spectroscopy, and X-Ray Diffraction Analysis

Dai, H., Yang, D., Liao, W., Wu, F. L., Zhou, Z., & Huang, Z. (2022) · Russian Journal of General Chemistry · doi:10.1134/s1070363222030112 · Cited by 5

Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma

Xin Min, Z. H. O. U., Sun, C., Wang, J., Mao, J., & Guo, H. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.023 · Cited by 5

Sugar amino acid based peptide epoxyketones as potential proteasome inhibitors

Risseeuw, M., Florea, B. I., van der Marel, G. A., Overkleeft, H. S., & Overhand, M. (2010) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2010.04.004 · Cited by 5

Roles of Estrogen Receptor and p21Waf1 in Bortezomib-Induced Growth Inhibition in Human Breast Cancer Cells

Maynadier, M., Shi, J., Vaillant, O., Gary‐Bobo, M., Basile, I., Gleizes, M., Cathiard, A. M., Wah, J. L. T., Sheikh, M. S., & Garcia, M. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0133 · Cited by 5

Influence of long-term proteasome inhibition on platelet responsiveness mediated by bortezomib

Klingler, P., Niklaus, M., Koessler, J., Weber, K., Koessler, A., Boeck, M., & Kobsar, A. L. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106830 · Cited by 5

γ-Glutamyltranspeptidase and γ-Glutamyl Peptide Ligases: Fluorophosphonate and Phosphonodifluoromethyl Ketone Analogs as Probes of Tetrahedral Transition State and γ-Glutamyl-Phosphate Intermediate

Hiratake, J., Inoue, M., & Sakata, K. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)54023-4 · Cited by 5

Inhibitory effect of bortezomib on human multiple myeloma cells when combined with epigallocatechin-gallate (EGCG) analogs

Pamu, S., Chen, D., Morin, F. G., Huo, C., Cui, Q. C., Dou, Q. P., & Chan, T. H. (2011) · MedChemComm · doi:10.1039/c1md00260k · Cited by 5

Ionic Interaction Effects on the Structure and Dynamics of Orthoborate Ionic Materials

Xu, Y., Reinholdt, A., Antzutkin, O. N., Forsyth, M., Johansson, P., & Shah, F. U. (2024) · Crystal Growth & Design · doi:10.1021/acs.cgd.4c01030 · Cited by 4

Synthesis of boronophenylalanine-like aza-amino acids for boron-containing azapeptide precursors

Miyata, K., Narita, A., Fujisawa, R., Roppongi, M., Ito, S., Shingo, T., & Oba, T. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.152585 · Cited by 4

Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004

Haas, M., & Lonial, S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.9.1161 · Cited by 4

Régulation de la protéolyse : l’action des protéasomes

Papapostolou, D., & Reboud‐Ravaux, M. (2004) · Journal de la Société de Biologie · doi:10.1051/jbio/2004198030263 · Cited by 4

Proteasome Inhibitors

Wehenkel, M., Ho, Y. K., & Kim, K. (2009) · Springer eBooks · doi:10.1007/978-0-387-69147-3_7 · Cited by 4

Proteasome Inhibitor Therapy in a Brain Tumor Model

Olson, J. J., Bowers, G. D., & Zhang, Z. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-794-9_13 · Cited by 3

Boronic Acid as a Promising Class of Chemical Entity for Development of Clinical Medicine for Targeted Therapy of Cancer

Watanabe, T., & Momose, I. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00173-3 · Cited by 3

The search for inhibitors of the ubiquitin–proteasome system from natural resources for drug development

Tsukamoto, S. (2006) · Journal of Natural Medicines · doi:10.1007/s11418-006-0002-1 · Cited by 3

Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells

Iijima, M., Momose, I., & Ikeda, D. (2010) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.100325 · Cited by 3

Incorporation of the Constrained Peptidomimetic, 5‐Methylpyridin‐2‐one into Peptide Vinyl Sulfones and Peptide Epoxy Ketones is Detrimental for Proteasome Inhibition

Xin, B., de Bruin, G., Plomp, J. J., Florea, B. I., van der Marel, G. A., & Overkleeft, H. S. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201501401 · Cited by 3

Preclinical Development of Bortezomib (VELCADE™)

Adams, J., Elliott, P. J., & Bouchard, P. R. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-794-9_19 · Cited by 3

Proteasome Inhibitors in Cancer Therapy and their Relation to Redox Regulation

Sarı, G., Okat, Z., Şahin, A., & Karademir-Yilmaz, B. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190201120013 · Cited by 3

The Proteasome in Aging

Carrard, G., & Friguet, B. (2003) · Springer eBooks · doi:10.1007/978-94-017-0667-4_14 · Cited by 3

Une nouvelle thérapie ciblée avec le bortézomib, médicament oncologique de l’année 2004

Monneret, C., Buisson, J., & Magdelénat, H. (2005) · Annales Pharmaceutiques Françaises · doi:10.1016/s0003-4509(05)82301-6 · Cited by 3

Novel Proteasome Inhibitors

Orlowski, R. Z. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5260-7_7 · Cited by 3

Protease Inhibitors: Mechanisms

Farady, C. J., & Craik, C. S. (2008) · Wiley eBooks · doi:10.1002/9780470048672.wecb474 · Cited by 3

Salicylaldimine dimers derived from 2-H2NC6H4Bpin (pin = 1,2-O2C2Me4)

Webb, J. D., Darwish, H. A., Zhang, H., Wheaton, S. L., Baerlocher, F. J., Vogels, C. M., Decken, A., & Westcott, S. A. (2005) · Canadian Journal of Chemistry · doi:10.1139/v05-124 · Cited by 3

Cancer

(2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1406 · Cited by 3

Prediction of Drug-Target Interactions Based on Hypergraph Neural Networks With Multimodal Feature Fusion

Zhang, Y., Li, J., Zhao, S. J., Tan, H., Sun, H., Xiong, Y., & Wei, D. (2025) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3625158 · Cited by 2

Highly diastereoselective synthesis of borylcyclopropanes by copper-catalyzed borylcyclopropanation of alkenes with enynones

Lu, F., Song, D., Sun, X., Zhi, L., Liu, X., Zhao, X., & Wang, G. (2026) · Chemical Communications · doi:10.1039/d6cc00756b · Cited by 2

The serendipitous integration of small boron-embedded molecules into medicinal chemistry

Abi-Ghaida, F. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822127-3.00006-5 · Cited by 2

An Exploration of Regioselectivity During Formation of Aminoboronates from Epoxides

Yudin, A. K., Trofimova, A., Brien, C., Tan, J., & Trudel, V. (2024) · Synlett · doi:10.1055/s-0043-1763674 · Cited by 2

Second-Generation Proteasome Inhibitors

Esseltine, D.-L. W., Dick, L., Kupperman, E., Williamson, M., & Anderson, K. C. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8948-2_11 · Cited by 2

Development of pseudopeptides and peptidomimetics as eukaryote proteasome inhibitors

Basse, N., Felten, A., Papapostolou, D., Bernard, E., Jamart‐Grégoire, B., Reboud‐Ravaux, M., & Vanderesse, R. (2009) · Comptes Rendus Chimie · doi:10.1016/j.crci.2009.03.003 · Cited by 2

A Brief Overview of Recent Advances in the Applications of Boro nic Acids Relevant to Glycomics

TA, S. M. H. (2014) · Journal of Glycomics & Lipidomics · doi:10.4172/2153-0637.1000e124 · Cited by 2

Straightforward synthesis of chiral non-racemic α-boryl isocyanides

Fini, F., Zanni, A., Introvigne, M. L., Stucchi, M., Caselli, E., & Prati, F. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob00616a · Cited by 2

Other Nonbiological Approaches to Targeted Cancer Chemotherapy

Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00011-9 · Cited by 2

Proteasome Activity and Immunosenescence

Friguet, B. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_38 · Cited by 2

COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT

Mehdi, S. (2013) · Wiley eBooks · doi:10.1002/9781118739907.ch3 · Cited by 2

Screening Combinatorial Peptide Libraries in Protease Inhibitor Drug Discovery

Poręba, M., Kasperkiewicz, P., Rut, W., & Drąg, M. (2018) · Wiley eBooks · doi:10.1002/9781119300229.ch11 · Cited by 2

1,2‐Metallate Rearrangement of Boron Derivatives

Bateman, J. M., & Aggarwal, V. K. (2019) · Patai's chemistry of functional groups · doi:10.1002/9780470682531.pat0973 · Cited by 2

Dichloromethyllithium

Albizati, K. F., & Matteson, D. S. (2005) · Wiley eBooks · doi:10.1002/047084289x.rd128 · Cited by 2

A Perspective on Covalent Inhibitors: Research and Development Trends of Warheads and TargetsPreprint

Chen, H., Bird, R. E., Wang, D.-S., Diaz, L. M. L., Iyer, K. A., Ralhan, K., Gustafson, G. R., Kato-Weinstein, J., & Zhou, Q. A. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-wf79n · Cited by 2

Nickel‐catalyzed Nucleophilic C‐Borylation of Imines

Ishibashi, H., Nishino, S., Shibata, K., & Kamei, T. (2023) · Chemistry - An Asian Journal · doi:10.1002/asia.202300437 · Cited by 1

Atom‐Economical Synthesis of Gem ‐Borylsilylalkanes by Copper‐Catalyzed SiH Bond Insertion of α ‐Furyl Boryl Carbenes

Song, D., Lu, F., Sun, X., Wang, G., & Zhao, X. (2026) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.70422 · Cited by 1

Molecular mechanisms underlying liposarcoma subtype transition and proteasome-associated targeted interventions

Liu, J., Huo, M., Wu, S., Wang, Z., Peng, S., & Fu, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08320-w · Cited by 1

Other Novel Targeted Therapies in Lung Cancer

Papadopoulos, K. P., & Tolcher, A. W. (2007) · CRC Press eBooks · doi:10.3109/9781420020359.007 · Cited by 1

Protein degradation-based cancer therapy

Avendaño, C., & Menéndez, J. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818549-0.00012-1 · Cited by 1

Boron‐10 carriers and their applications in boron neutron capture therapy

Tang, D., Shi, M., Mao, Z., Chen, W., Li, X. Y., Zhao, X., Liu, Z., & Xu, L. (2026) · Precision Radiation Oncology · doi:10.1002/pro6.70061 · Cited by 1

Holistic Molecular Approaches for Anticancer Therapy

Chashoo, G., Singh, S. K., Ahmed, Q. N., & Saxena, A. K. (2012) · Journal of Biomedical and Pharmaceutical Research · Cited by 1

Substrate screening identifies a novel target sequence for the proteasomal activity regulated by ionizing radiation

Broggini‐Tenzer, A., Hollenstein, A., Pianowski, Z., Wampfler, A., Furmanova, P., Winssinger, N., & Pruschy, M. N. (2009) · PROTEOMICS · doi:10.1002/pmic.200900162 · Cited by 1

β-Silyloxy allylboronate esters through an aldehyde borylation/homologation sequence

Meyer, G. F., Nistler, M. A., Samoshin, A. V., McManus, B. D., Thane, T. A., Ferber, C. J., O’Neil, G. W., & Clark, T. B. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.152082 · Cited by 1

Development of novel chemical tools for proteasome biology & a new approach to 1-azaspirocyclic ring system

Kumar, L. (2012) · UKnowledge (University of Kentucky) · Cited by 1

Boron-containing small molecules as antiparasitic agents

Coghi, P. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822127-3.00001-6 · Cited by 1

Quantum Evaluation of a Comprehensive Set of Carboxylic Acid Bioisosteres: Gas versus Solvated Phases

Osman, A. M., & Arabi, A. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c11714 · Cited by 1

Other Approaches to Targeted Therapy

Avendaño, C., & Menéndez, J. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-444-52824-7.00010-x · Cited by 1

Elucidating Proteasome Catalytic Subunit Composition and Its Role in Proteasome Inhibitor Resistance

Carmony, K. C. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.173 · Cited by 1

Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance

Ao, L. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2017.004 · Cited by 1

ChemInform Abstract: Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids.

Adams, J., Behnke, M. L., CHEN, S., Cruickshank, A., Dick, L. R., Grenier, L., Klunder, J. M., MA, Y. ‐., Plamondon, L., & Stein, R. L. (1998) · ChemInform · doi:10.1002/chin.199821191 · Cited by 1

The Development of Novel Proteasome Inhibitors for the Treatment of Multiple Myeloma and Alzheimer's Disease

Lee, M. J. (2019) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2019.169 · Cited by 1

ChemInform Abstract: Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids.

Adams, J., Behnke, M. L., CHEN, S., Cruickshank, A., Dick, L. R., Grenier, L., Klunder, J. M., MA, Y. ‐., Plamondon, L., & Stein, R. L. (1998) · ChemInform · doi:10.1002/chin.199821191 · Cited by 1

α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity

Benedik, N. S., Šterman, A., Smrdel, L., Pajk, S., Gobec, S., Časar, Z., Gobec, M., & Sosič, I. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02548 · Cited by 3

Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

Zhu, Y., Wu, G., Zhu, X., Ma, Y., Zhao, X., Li, Y., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1009742 · Cited by 38

Synthesis, in Vitro and in Vivo Biological Evaluation, Docking Studies, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronic Acid Proteasome Inhibitors Composed of β-Amino Acids

Zhu, Y., Zhu, X., Wu, G., Ma, Y., Li, Y., Zhao, X., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901407s · Cited by 39

Design, Synthesis, Biological Evaluation, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates

Zhu, Y., Zhao, X., Zhu, X., Wu, G., Li, Y., Ma, Y., Yuan, Y., Yang, J., Hu, Y., Ai, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9005093 · Cited by 75